These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37921049)

  • 1. Evaluating physiochemical properties of FDA-approved orally administered drugs.
    Reese TC; Devineni A; Smith T; Lalami I; Ahn JM; Raj GV
    Expert Opin Drug Discov; 2024 Feb; 19(2):225-238. PubMed ID: 37921049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Going further than Lipinski's rule in drug design.
    Walters WP
    Expert Opin Drug Discov; 2012 Feb; 7(2):99-107. PubMed ID: 22468912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five.
    Stegemann S; Moreton C; Svanbäck S; Box K; Motte G; Paudel A
    Drug Discov Today; 2023 Feb; 28(2):103344. PubMed ID: 36442594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption matters: A closer look at popular oral bioavailability rules for drug approvals.
    Caminero Gomes Soares A; Marques Sousa GH; Calil RL; Goulart Trossini GH
    Mol Inform; 2023 Nov; 42(11):e202300115. PubMed ID: 37550251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
    Doak BC; Over B; Giordanetto F; Kihlberg J
    Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular inflation, attrition and the rule of five.
    Leeson PD
    Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Drug-likeness Rules Apply to Oral Prodrugs?
    Protti ÍF; Rodrigues DR; Fonseca SK; Alves RJ; de Oliveira RB; Maltarollo VG
    ChemMedChem; 2021 May; 16(9):1446-1456. PubMed ID: 33471444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five.
    Chen X; Li H; Tian L; Li Q; Luo J; Zhang Y
    J Comput Biol; 2020 Sep; 27(9):1397-1406. PubMed ID: 32031890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship.
    Andrews CW; Bennett L; Yu LX
    Pharm Res; 2000 Jun; 17(6):639-44. PubMed ID: 10955834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ask the experts: past, present and future of the rule of five.
    Baell J; Congreve M; Leeson P; Abad-Zapatero C
    Future Med Chem; 2013 May; 5(7):745-52. PubMed ID: 23651089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiochemical property space distribution among human metabolites, drugs and toxins.
    Khanna V; Ranganathan S
    BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S10. PubMed ID: 19958509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space.
    Caron G; Digiesi V; Solaro S; Ermondi G
    Drug Discov Today; 2020 Apr; 25(4):621-627. PubMed ID: 31991117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery beyond the 'rule-of-five'.
    Zhang MQ; Wilkinson B
    Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.
    Shultz MD
    J Med Chem; 2019 Feb; 62(4):1701-1714. PubMed ID: 30212196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eyes on Lipinski's Rule of Five: A New "Rule of Thumb" for Physicochemical Design Space of Ophthalmic Drugs.
    Karami TK; Hailu S; Feng S; Graham R; Gukasyan HJ
    J Ocul Pharmacol Ther; 2022; 38(1):43-55. PubMed ID: 34905402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space.
    Poongavanam V; Doak BC; Kihlberg J
    Curr Opin Chem Biol; 2018 Jun; 44():23-29. PubMed ID: 29803972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options.
    Aungst BJ
    J Pharm Sci; 2017 Apr; 106(4):921-929. PubMed ID: 27986598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rule of five for non-oral routes of drug delivery: ophthalmic, inhalation and transdermal.
    Choy YB; Prausnitz MR
    Pharm Res; 2011 May; 28(5):943-8. PubMed ID: 20967491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules.
    Yang W; Gadgil P; Krishnamurthy VR; Landis M; Mallick P; Patel D; Patel PJ; Reid DL; Sanchez-Felix M
    AAPS J; 2020 Jan; 22(2):21. PubMed ID: 31900602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.